Extracellular vesicle (EV)-associated microRNAs (miRNAs) have been found as the important biomarkers participating in the development of osteonecrosis of the femoral head (ONFH). Consequently, this study sought to examine the underlying mechanism of bone marrow mesenchymal stem cell (BMSC)-derived EVs containing miR-148a-3p in ONFH. The ONFH rat models were established. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western blot analysis were applied to detect miR-148a-3p, Smad ubiquitination regulatory factor 1 (SMURF1), SMAD7 and B-cell CLL/lymphoma 2 (BCL2) expression, followed by determination of relationship between miR-148a-3p and SMURF1. BMSCs were isolated from normal rats and ONFH rats, and EVs were extracted from BMSCs of normal rats. BMSCs from ONFH rats were treated with mimic, inhibitor, small interfering RNA or EVs from miR-148a-3p mimic-treated BMSCs from normal rats (BMSC-EV-miR-148a-3p mimic). Cell Counting Kit-8 and alizarin red staining were utilized to detect cell viability and osteogenic differentiation of BMSCs. ONFH rats were injected with BMSC-EV-miR-148a-3p mimic to explore the function of BMSC-EV-delivered miR-148a-3p in vivo. miR-148a-3p was down-regulated in BMSCs and EVs from ONFH rats following decreased BMSCs viability and osteogenic differentiation. SMURF1 was a target gene of miR-148a-3p, and resulted in ubiquitination and degradation of SMAD7 to decreased BCL2 expression. The proliferation and differentiation of BMSCs were promoted by BMSC-EV-miR-148a-3p mimic or SMURF1 silencing. Additionally, BMSC-EV-miR-148a-3p mimic increased cell proliferation and osteogenic response, diminished SMURF1 expression, and elevated SMAD7 and BCL2 expression in ONFH rats. Collectively, miR-148a-3p overexpressed in BMSC-EVs promoted SMAD7 and BCL2 expression by inhibiting SMURF1, thus alleviating ONFH.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576243PMC
http://dx.doi.org/10.1111/jcmm.15766DOI Listing

Publication Analysis

Top Keywords

onfh rats
20
bcl2 expression
16
bmsc-ev-mir-148a-3p mimic
16
normal rats
12
onfh
9
bone marrow
8
marrow mesenchymal
8
mesenchymal stem
8
osteonecrosis femoral
8
femoral head
8

Similar Publications

The early treatment of Osteonecrosis of Femoral Head (ONFH) remains a clinical challenge. Conventional Bone Marrow Mesenchymal Stem Cell (BMSC) injection methods often result in unsatisfactory outcomes due to mechanical cell damage, low cell survival and retention rates, inadequate cell matrix accumulation, and poor intercellular interaction. In this study, we employed a novel cell carrier material termed "3D Microscaffold" to deliver BMSCs, addressing these issues and enhancing the therapeutic effects of cell therapy for ONFH.

View Article and Find Full Text PDF

Methylprednisolone (MPS) use is linked to increased cases of osteonecrosis of the femoral head (ONFH). Bone marrow mesenchymal stem cells (BMSCs) have shown potential for treating MPS-induced ONFH, but their effectiveness is limited by high apoptosis rates post-transplantation. We developed a pre-treatment strategy for BMSCs to improve their viability.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on how steroid-induced femoral head osteonecrosis (ONFH) is linked to an imbalance in bone homeostasis, particularly through the effects of bone marrow-derived mesenchymal stem cells (BMSCs).
  • Inhibiting monoacylglycerol lipase (MAGL) has shown promise in improving ONFH by reducing oxidative stress and promoting the differentiation of BMSCs towards bone-forming cells instead of fat cells.
  • The research identifies the cannabinoid receptor 2 (CB2) as the key receptor involved in this process and highlights that MAGL inhibition helps maintain bone balance by suppressing bone resorption and influencing pathways related to BMSC differentiation.
View Article and Find Full Text PDF

Alpha-2-macroglobulin mitigates glucocorticoid-induced osteonecrosis via Keap1/Nrf2 pathway activation.

Free Radic Biol Med

November 2024

Department of Orthopedic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, PR China; Department of Sports Medicine, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, PR China; Fujian Orthopaedics Research Institute, Fuzhou, 350000, PR China; Fujian Orthopedic Bone and Joint Disease and Sports Rehabilitation Clinical Medical Research Center, Fuzhou, 350000, PR China. Electronic address:

Glucocorticoids (GCs) are widely prescribed for various medical conditions, but prolonged use can result in osteonecrosis of the femoral head (ONFH), a serious condition characterized by bone tissue death due to reduced blood flow. Alpha-2-macroglobulin (A2M) is known to regulate oxidative stress and has been implicated in numerous biological processes. However, its role in GCs-induced ONFH has not been fully elucidated.

View Article and Find Full Text PDF

SOST/Sclerostin impairs the osteogenesis and angiogesis in glucocorticoid-associated osteonecrosis of femoral head.

Mol Med

September 2024

Department of Orthopaedics, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Xuhui District, Shanghai, 200032, China.

Article Synopsis
  • Glucocorticoid-associated osteonecrosis of the femoral head (GA-ONFH) leads to bone damage and hip dysfunction, with sclerostin playing a key role in bone health and breakdown.
  • The study used various cell models and animal models to examine how sclerostin affects bone cells under glucocorticoid treatment.
  • Results showed that high levels of sclerostin contribute to the progression of GA-ONFH by hindering bone growth and blood vessel formation, highlighting its potential as a target for treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!